Ematologia- Ospedale Businco
Welcome,         Profile    Billing    Logout  
 4 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ANGELUCCI, Emanuele
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FISM_registry, NCT02808858: Italian Network MDS Registry

Recruiting
N/A
10000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Myelodysplastic-Myeloproliferative Diseases
06/16
05/32
NCT03620318: Individual Patient Compassionate Use of Crenolanib

Available
N/A
Europe
Crenolanib besylate
Arog Pharmaceuticals, Inc.
FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V, PDGFRA Gene Amplification
 
 
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
FISiM-NGS-MDS, NCT04212390: Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care

Completed
N/A
1000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
MDS (Myelodysplastic Syndrome)
07/24
07/24
Crisà, Elena
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27
FISM_registry, NCT02808858: Italian Network MDS Registry

Recruiting
N/A
10000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Myelodysplastic-Myeloproliferative Diseases
06/16
05/32
FISiM-NGS-MDS, NCT04212390: Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care

Completed
N/A
1000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
MDS (Myelodysplastic Syndrome)
07/24
07/24
GIMEMA, NCT06657846: HRQoL and Financial Toxicity in Patients with VEXAS Syndrome

Not yet recruiting
N/A
100
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
VEXAS
02/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ANGELUCCI, Emanuele
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FISM_registry, NCT02808858: Italian Network MDS Registry

Recruiting
N/A
10000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Myelodysplastic-Myeloproliferative Diseases
06/16
05/32
NCT03620318: Individual Patient Compassionate Use of Crenolanib

Available
N/A
Europe
Crenolanib besylate
Arog Pharmaceuticals, Inc.
FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V, PDGFRA Gene Amplification
 
 
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
FISiM-NGS-MDS, NCT04212390: Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care

Completed
N/A
1000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
MDS (Myelodysplastic Syndrome)
07/24
07/24
Crisà, Elena
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27
FISM_registry, NCT02808858: Italian Network MDS Registry

Recruiting
N/A
10000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Myelodysplastic-Myeloproliferative Diseases
06/16
05/32
FISiM-NGS-MDS, NCT04212390: Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care

Completed
N/A
1000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
MDS (Myelodysplastic Syndrome)
07/24
07/24
GIMEMA, NCT06657846: HRQoL and Financial Toxicity in Patients with VEXAS Syndrome

Not yet recruiting
N/A
100
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
VEXAS
02/25
06/25

Download Options